Madrigal Pharmaceuticals, Inc. MDGL Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Madrigal Pharmaceuticals, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s operating income?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported operating income of -$92.72M in Q1 2026.
- How has Madrigal Pharmaceuticals, Inc.'s operating income changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s operating income decreased by 16.9% year-over-year, from -$79.31M to -$92.72M.
- What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s operating income?
- Over 4 years (2021 to 2025), Madrigal Pharmaceuticals, Inc.'s operating income has grown at a 5.5% compound annual growth rate (CAGR), from -$242.48M to -$300.1M.
- What does operating income mean?
- The profit a company makes from its core business operations before interest and taxes.
- How do you interpret operating income?
- An increase signals improved profitability and operational efficiency, while a decrease indicates declining margins or rising operational costs.
- How does operating income compare across companies?
- Many clinical-stage biotechs operate at a loss; achieving positive operating income is a major milestone for maturing companies.